Ose, Jennifer
Schock, Helena
Poole, Elizabeth M.
Lehtinen, Matti
Visvanathan, Kala
Helzlsouer, Kathy
Buring, Julie E.
Lee, I-Min
Tjønneland, Anne
Boutron-Ruault, Marie-Christine
Trichopoulou, Antonia
Mattiello, Amalia
Onland-Moret, N. Charlotte
Weiderpass, Elisabete
Sánchez, María-José
Idahl, Annika
Travis, Ruth C.
Rinaldi, Sabina
Merritt, Melissa A.
Wentzensen, Nicolas
Tworoger, Shelley S.
Kaaks, Rudolf
Fortner, Renée T. http://orcid.org/0000-0002-1426-8505
Funding for this research was provided by:
Seventh Framework Programme (MC-IIF-623984)
U.S. Department of Defense (W81XWH-12-1-0561)
National Cancer Institute (R01 CA120061, UM1 CA176726, R01 CA67262, CA97857, CA86308)
National Cancer Institute (UM1 CA186107, P01 CA87969)
National Heart, Lung, and Blood Institute (HL043851, HL080467, HL099355)
Article History
Received: 18 October 2016
Accepted: 16 January 2017
First Online: 16 February 2017
Compliance with ethical standards
:
: No potential conflicts of interest were disclosed.
: The authors assume full responsibility for analyses and interpretation of these data.
: The OC3 is supported by Department of Defense Ovarian Cancer Research Program Grant No. W81XWH-12-1-0561. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada; PI13/01162 to EPIC-Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). Support was provided by the following National Institutes of Health/NCI grants: R01 CA120061 (Finnish Maternity Cohort); UM1 CA186107, P01 CA87969, UM1 CA176726, and R01 CA67262 (Nurses’ Health Study, Nurses’ Health Study II); HL043851, HL080467, and HL099355 (Women’s Health Study). CLUEII was supported by National Cancer Institute grant numbers: CA-97857, CA-86308; Grant sponsor: M. Jean Goutal (donation): Grant sponsors: The Woodrow Wilson Foundation/Johnson and Johnson, The Lloyds TSB Charitable Foundation for the Channel Islands. RT Fortner was supported by a Marie Curie International Incoming Fellowship of the European Commission’s Seventh Framework Programme (MC-IIF-623984).